← All indications
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
Drugs by status
Approved for this indication (1)
Phase 4 trials (5)
Phase 3 trials (41)
- fda018-adc
- fluzoparib
- olaparib
- camrelizumab
- everolimus
- doxorubicin
- dexamethasone
- cytarabine
- hlx10
- epirubicin
- lapatinib
- vinorelbine
- triprizumab
- eribulin
- moxifloxacin
- ifosfamide
- cyclophosphamide
- zoledronic acid
- adagloxad simolenin
- skb264
- pembrolizumab
- oxaliplatin
- avelumab
- utidelone
- capecitabine
- Filgrastim
- prednisolone
- capivasertib
- alpelisib
- gemcitabine
- +11 more
Phase 2 trials (235)
Phase 1 trials (138)
- rx-5902
- abbv-400
- atrc-101
- nkt3447
- ly3300054
- pepticrad-1
- alx148
- ltx-315
- vocimagene amiretrorepvec
- mgd013
- personalized synthetic long peptide vaccine
- ly3435151
- ferumoxytol
- pba-0405
- ro7198457
- personalized polyepitope dna vaccine
- tak-676
- abiraterone
- sargramostim
- autologous dendritic cells loaded with autologous tumor lysate
- cmet cart cells
- ag-01
- flucytosine
- nm1f
- ly4175408
- fluoromisonidazole
- Zanidatamab
- xl102
- poly-iclc
- faz053
- +108 more
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (49)
- AbbVie
- Eisai
- Celgene
- Astellas
- Immunomedics
- AstraZeneca
- Medivation
- Merck
- Genentech
- Pfizer
- Novartis
- ERYtech Pharma
- Hengrui Therapeutics, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- OBI Pharma, Inc
- Shanghai Henlius Biotech
- Shanghai Junshi Bioscience Co.,Ltd.
- National Cancer Institute (NCI)
- Changhai Hospital
- China Breast Cancer Clinical Study Group
- Danish Breast Cancer Cooperative Group
- Finnish Breast Cancer Group
- Istituto Oncologico Veneto IRCCS
- Lund University
- Tata Memorial Hospital
- University of Milan
- University of Padova
- Yonsei University
- Zhejiang University
- Alliance Foundation Trials
- +19 more
Organization Involved with Phase 2 Indications (234)
- Pierre Fabre
- Zenith Epigenetics
- Incyte
- Daiichi Sankyo
- Seattle Genetics
- Takeda
- Bristol-Myers Squibb
- Amgen
- Clovis Oncology
- Servier
- Genmab
- Merck Serono
- Eli Lilly
- Exelixis
- Merck KGaA
- Sanofi
- Array BioPharma
- Union Therapeutics
- AurKa Pharma Inc.
- BeOne Medicines
- BioLite, Inc.
- Biothera
- Cancer Insight, LLC
- CASI Pharmaceuticals, Inc.
- Celldex Therapeutics
- Effector Therapeutics
- Esperas Pharma Inc.
- Endocyte
- G1 Therapeutics, Inc.
- GlaxoSmithKline
- +204 more
Organization Involved with Phase 1 Indications (50)
- ADC Therapeutics SARL
- OncoEthix
- Millennium Pharmaceuticals
- MedImmune
- Curis
- Ipsen
- Wyeth
- Biocon Limited
- Corcept Therapeutics
- Corvus Pharmaceuticals, Inc.
- IRX Therapeutics
- Lytix Biopharma AS
- MacroGenics
- Moderna Therapeutics
- OncoTherapy Science, Inc.
- Piramal
- PharmAbcine
- Rexahn Pharmaceuticals, Inc.
- Theradex
- Tocagen Inc.
- Forbius
- The Methodist Hospital System
- University of Pennsylvania
- Universidad Nacional de Colombia
- University of Miami
- University of Southern California
- University of Virginia
- Columbia University
- Peking University
- Tel Aviv University
- +20 more
Organization Involved with Other Experimental Indications (3)